Ocuphire's historical pipeline included APX3330, an oral small-molecule inhibitor of Ref-1 being developed for diabetic retinopathy, and Phentolamine Ophthalmic Solution 0.75%, designed to reduce pupil size. The company's strategy evolved from small-molecule ophthalmic drugs toward adeno-associated virus-based gene therapies for inherited retinal diseases under the Opus Genetics name.
Cyborg Score Rationale
The company has a market cap of approximately $30.7M, classified as a micro-cap stock. The stock has lost 59.4% over the past 12 months. The company is navigating significant strategic restructuring post-acquisition with execution risks.
Top Insights
Company rebranded as Opus Genetics (October 2024) following acquisition, now trading under ticker IRD on NASDAQ
Shifted focus from small-molecule ophthalmic treatments to AAV-based gene therapies for rare inherited retinal diseases
Micro-cap status ($30.7M market cap) with significant stock decline over past 12 months, indicating market skepticism
Historical product pipeline (APX3330 for diabetic retinopathy, Nyxol Eye Drops) now under legacy OCUP ticker reference
Named Competitors
Luxturna — AAV gene therapy for inherited retinal dystrophy